Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368-Reference-Cited by-同舟云学术

Comparative Activity and Off-Target Effects in Cells of the CHK1 Inhibitors MK-8776, SRA737, and LY2606368

Published:2021-02-12 Issue:2 Volume:4 Page:730-743
ISSN:2575-9108
Container-title:ACS Pharmacology & Translational Science
language:en
Short-container-title:ACS Pharmacol. Transl. Sci.

Author:

Ditano Jennifer P.¹,Eastman Alan¹^ORCID

Affiliation:

1. Department of Molecular and Systems Biology and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire 03756, United States

Funder

National Cancer Institute

Publisher

American Chemical Society (ACS)

Subject

Pharmacology (medical),Pharmacology

Link

https://pubs.acs.org/doi/pdf/10.1021/acsptsci.0c00201

Reference33 articles.

1. The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

2. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription

3. Loss of ATM/Chk2/p53 Pathway Components Accelerates Tumor Development and Contributes to Radiation Resistance in Gliomas

4. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase

5. Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological evaluation of glucose metabolism inhibitors as anticancer agents;Bioorganic Chemistry;2024-10

2. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

3. Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy;European Journal of Medicinal Chemistry;2024-04

4. Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors;Critical Reviews in Oncology/Hematology;2024-01

5. Double‐strand DNA break repair: molecular mechanisms and therapeutic targets;MedComm;2023-10